CD274 and neoplasm: Additionally, IBI322, a CD47/PD-L1 BsAb which attenuates CD47 activity in monovalent binding and blocks PD-L1 activity in bivalent binding, was designed by Wang et al. to enhance anti-tumor activity in PD-L1-expressing solid tumors both in vitro and in vivo [63].